Company intelligence / Profile preview
Primo Biotech
St. Louis, Missouri, United Statesprimobiotech.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Primo Biotech is a pre-clinical stage biotechnology company focused on developing novel therapeutic solutions for inflammatory conditions and pain management. The company's primary research centers on the modulation of the Prostaglandin E2 (PGE2) pathway, specifically targeting the EP4 receptor to treat conditions such as osteoarthritis. By utilizing a targeted approach to inflammation, Primo Biotech aims to provide effective pain relief while minimizing the systemic side effects often associated with traditional non-steroidal anti-inflammatory drugs (NSAIDs). Their lead programs are currently in the optimization and early validation phases.
- Therapeutic areas
- NeurologyImmunologyRheumatology
- Modalities
- Small moleculePeptides
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Primo Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Primo Biotech.